Skip to main content
OpenTrials
Completed

NCT Number: NCT02265640

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

The objective of the present study is to investigate the relative bioavailability of BIIL 284 BS boli in comparison to the tablet C at a dose of 75 mg in fasted condition and after a standard breakfast in healthy male volunteers

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

21 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All participants are healthy males
  • Age range from 21 to 50 years
  • Broca-Index: within +- 20% of normal weight

Exclusion criteria

  • Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy) or with psychiatric disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of a drug with a long half-life (> 24 hours) within one month or less than ten half-lives of the respective drug before enrollment in the study
  • Use of any drugs which might influence the results of the trial (>= one week prior to administration or during the trial)
  • Participation in another study with an investigational drug (>= tow months prior to administration or during the trial)
  • Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
  • Inability to refrain from smoking on study days
  • Alcohol abuse (> 60g/day)
  • Drug abuse
  • Blood donation (>= 100 mL) within four weeks prior to administration or during the trial
  • Excessive physical activities (within the last week before the study)
  • Any laboratory value outside the reference range of clinical relevance

Treatment and study plan

BIIL 284 BS boli

Drug

BIIL 284 BS tablet C

Drug

standard breakfast

Other

Primary outcomes

  1. Plasma levels of BIIL 315 ZW

    Time frame: up to 72 hours after drug administration

  2. AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: up to 72 hours after drug administration

  3. Cmax (Maximum measured concentration of the analyte in plasma)

    Time frame: up to 72 hours after drug administration

Secondary outcomes

  1. tmax (Time from dosing to the maximum concentration of the analyte in plasma)

    Time frame: up to 72 hours after drug administration

  2. t½ (Terminal half-life of the analyte in plasma)

    Time frame: up to 72 hours after drug administration

  3. MRTtot (Total mean residence time)

    Time frame: up to 72 hours after drug administration

  4. Vz/F (Apparent volume of distribution of the analyte during the terminal phase)

    Time frame: up to 72 hours after drug administration

  5. CLtot/F (Total clearance after oral administration)

    Time frame: up to 72 hours after drug administration

  6. Number of subjects with adverse events

    Time frame: up to 8 days after last drug administration

  7. Number of subjects with clinically significant findings in vital functions

    Time frame: up to 8 days after last drug administration

    blood pressure, pulse rate, ECG

  8. Number of subjects with clinically significant findings in laboratory tests

    Time frame: up to 8 days after last drug administration

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Randomised 4-way Cross-over Phase I Study to Investigate the Relative Bioavailability of BIIL 284 BS 75 mg Boli in Comparison to Tablet C in Fasted Condition and After Ingestion of a Standardised Meal in Healthy Volunteers

Important dates

Study start
2000
Primary completion
2000
First posted
Oct 16, 2014
Registry last updated
Oct 16, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.